Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

ClinicalTrials.gov ID: NCT01232556

Public ClinicalTrials.gov record NCT01232556. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN ADMINISTERED IN COMBINATION WITH RITUXIMAB COMPARED TO DEFINED INVESTIGATOR'S CHOICE THERAPY IN SUBJECTS WITH RELAPSED OR REFRACTORY CD22-POSITIVE AGGRESSIVE NON-HODGKIN LYMPHOMA WHO ARE NOT CANDIDATES FOR INTENSIVE HIGH-DOSE CHEMOTHERAPY

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin plus rituximab in relapsed/refractory aggressive Non-Hodgkin lymphoma patients who are not candidates for intensive high-dose chemotherapy. Specifically, the goal is to demonstrate the superiority of this combination compared with an active comparator arm (investigator's choice of rituximab+bendamustine or rituximab+gemcitabine) using the primary endpoint of overall survival.

Study identification

NCT ID
NCT01232556
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
338 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 4, 2011 (Actual)
Primary completion
Mar 28, 2014 (Actual)
Completion
Mar 28, 2014 (Actual)
Last update posted
Jan 8, 2019

2011 – 2014

United States locations

U.S. sites
82
U.S. states
21
U.S. cities
45
Facility City State ZIP Site status
Disney Family Cancer Center at Providence St Joseph Medical Center Burbank California 91505 —
Providence St Joseph Medical Center Burbank California 91505 —
Hematology-Oncology Medical Group of Fresno Inc Fresno California 93720 —
Ronald Reagan UCLA Medical Center Drug Information Center Department of Pharmaceutical Services Los Angeles California 90095-6981 —
Clinical Research Unit Los Angeles California 90095 —
Peter Morton Medical Plaza Los Angeles California 90095 —
Ronald Reagan UCLA Medical Center Los Angeles California 90095 —
Sansum Clinic Santa Barbara California 93105 —
UCLA Santa Monica Hematology Oncology Santa Monica California 90404 —
Sansum Clinic Solvang California 93463 —
Howard University Hospital Washington D.C. District of Columbia 20060 —
Mount Sinai Comprehensive Cancer Center at Aventura Aventura Florida 33180 —
University Cancer Institute Boynton Beach Florida 33426 —
21st Century Oncology of Jacksonville, LLC Fernandina Beach Florida 32034 —
Davis Cancer Pavilion and Shands Medical Plaza Gainesville Florida 32608 —
Shands Cancer Hospital at the University of Florida Gainesville Florida 32608 —
UF Health Davis Cancer Pavillion and Shands Med Plaza Gainesville Florida 32608 —
UF Health Shands Cancer Hospital Gainesville Florida 32608 —
Shands Hospital at the University of Florida Gainesville Florida 32610 —
UF Health Shands Hospital Gainesville Florida 32610 —
21st Century Oncology of Jacksonville, LLC Jacksonville Florida 32205 —
21st Century Oncology of Jacksonville, LLC Jacksonville Florida 32207 —
Baptist Cancer Institute Jacksonville Florida 32207 —
Baptist Medical Center Jacksonville Florida 32207 —
21st Century Oncology of Jacksonville, LLC Jacksonville Florida 32256 —
21st Century Oncology of Jacksonville, Inc. Jacksonville Florida 32258 —
Medical Specialists Of The Palm Beaches Lake Worth Florida 33467 —
Advanced Medical Specialties Miami Florida 33133 —
Mercy Hospital Miami Florida 33133 —
Mercy Research Institute Miami Florida 33133 —
Mount Sinai Comprehensive Cancer Center Miami Beach Florida 33140 —
Mount Sinai Medical Center Miami Beach Florida 33140 —
21st Century Oncology of Jacksonville, LLC Orange Park Florida 32073 —
Georgia Regents Medical Cancer Pharmacy Augusta Georgia 30912 —
Georgia Regents University Augusta Georgia 30912 —
Kootenai Cancer Center Coeur d'Alene Idaho 83814 —
Kootenai Cancer Center Post Falls Idaho 083854 —
Decatur Memorial Hospital (DMH) Decatur Illinois 62526 —
Floyd Memorial Cancer Center of Indiana New Albany Indiana 47150 —
University of Kansas Medical Center Kansas City Kansas 66160 —
University of Kansas Cancer Center and Medical Pavilion Westwood Kansas 66205 —
University of Kentucky A.B. Chandler Medical Center Lexington Kentucky 40536 —
University of Kentucky Markey Cancer Center Lexington Kentucky 40536 —
Tulane University Hospital and Clinic New Orleans Louisiana 70112 —
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201 —
Barbara Ann Karmanos Cancer Institute at farmington Hills Farmington Hills Michigan 48334 —
Park Nicollet Frauenshuh Cancer Center Saint Louis Park Minnesota 55426 —
Barnes-Jewish St. Peters City of Saint Peters Missouri 63376 —
Barnes-Jewish Hospital St Louis Missouri 63110 —
Washington University in St Louis St Louis Missouri 63110 —
Washington University School of Medicine St Louis Missouri 63110 —
Washington University St Louis Missouri 63110 —
Southeast Nebraska Hematology & Oncology Consultants, P.C. d/b/a Southeast Nebraska Cancer Center Lincoln Nebraska 68510 —
Beth Israel Medical Center; New York New York 10003 —
Beth Israel Comprehensive Cancer Center New York New York 10011-5903 —
St Luke's- Roosevelt Hospital Center New York New York 10019 —
Memorial Sloan Kettering Cancer Center New York New York 10065 —
Stony Brook University Medical Center, The Cancer Center Stony Brook New York 11794 —
Stony Brook University Medical Center Stony Brook New York 11794 —
University Hospital Cincinnati Ohio 45219 —
West Chester Hospital Medical Building West Chester Ohio 45069 —
OU Medical Center Presbyterian Professional Building Oklahoma City Oklahoma 73104 —
OU Medical Center Presbyterian Tower Oklahoma City Oklahoma 73104 —
Peggy and Charles Stephenson Cancer Center (chemo & infusion) Oklahoma City Oklahoma 73104 —
Peggy and Charles Stephenson Cancer Center (clinic location) Oklahoma City Oklahoma 73104 —
Good Samaritan Hospital Corvallis Corvallis Oregon 97330 —
Good Samaritan Hospital, Corvallis Corvallis Oregon 97330 —
Samaritan Ambulatory Infusion Services Corvallis Oregon 97330 —
Samaritan Pacific Coast Hospital Newport Oregon 97365 —
Penn State Milton S. Hershey Medical Center Hershey Pennsylvania 17033 —
Guthrie Clinic, Ltd. Sayre Pennsylvania 18840 —
Robert Packer Hospital Sayre Pennsylvania 18840 —
Thompson Oncology Group Knoxville Tennessee 37916 —
Thompson Oncology Group Knoxville Tennessee 37932 —
Thompson Oncology Group Maryville Tennessee 37804 —
Thompson Oncology Group Sevierville Tennessee 37862 —
University Hospital - St. Paul Dallas Texas 75235 —
University Hospital - Zale Lipshy Dallas Texas 75235 —
Baylor University Medical Center Dallas Texas 75246 —
Baylor: Charles A. Sammons Cancer Center Dallas Texas 75246 —
Simmons Comprehensive Cancer Center Dallas Texas 75390 —
The University of Texas MD Anderson Cancer Center Houston Texas 77030 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 95 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01232556, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 8, 2019 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01232556 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →